<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing3.dtd?>
<?SourceDTD.Version 3.0?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Oncotarget</journal-id>
    <journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id>
    <journal-id journal-id-type="publisher-id">Oncotarget</journal-id>
    <journal-id journal-id-type="publisher-id">ImpactJ</journal-id>
    <journal-title-group>
      <journal-title>Oncotarget</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1949-2553</issn>
    <publisher>
      <publisher-name>Impact Journals LLC</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5354899</article-id>
    <article-id pub-id-type="pmid">28042959</article-id>
    <article-id pub-id-type="publisher-id">14107</article-id>
    <article-id pub-id-type="doi">10.18632/oncotarget.14107</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Paper</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Hidalgo</surname>
          <given-names>Marta R.</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cubuk</surname>
          <given-names>Cankut</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Amadoz</surname>
          <given-names>Alicia</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="A2">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Salavert</surname>
          <given-names>Francisco</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="A3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Carbonell-Caballero</surname>
          <given-names>José</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dopazo</surname>
          <given-names>Joaquin</given-names>
        </name>
        <xref ref-type="aff" rid="A1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="A2">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="A3">
          <sup>3</sup>
        </xref>
      </contrib>
    </contrib-group>
    <aff id="A1"><sup>1</sup> Computational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, 46012, Spain</aff>
    <aff id="A2"><sup>2</sup> Functional Genomics Node (INB-ELIXIR-es), Valencia, 46012, Spain</aff>
    <aff id="A3"><sup>3</sup> Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, 46012, Spain</aff>
    <author-notes>
      <corresp id="cor1">
        <bold>
          <italic>Correspondence to:</italic>
        </bold>
        <italic>Joaquín Dopazo,</italic>
        <email>jdopazo@cipf.es</email>
      </corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>17</day>
      <month>1</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>12</month>
      <year>2016</year>
    </pub-date>
    <volume>8</volume>
    <issue>3</issue>
    <fpage>5160</fpage>
    <lpage>5178</lpage>
    <history>
      <date date-type="received">
        <day>1</day>
        <month>9</month>
        <year>2016</year>
      </date>
      <date date-type="accepted">
        <day>21</day>
        <month>11</month>
        <year>2016</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright: © 2017 Hidalgo et al.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Understanding the aspects of the cell functionality that account for disease or drug action mechanisms is a main challenge for precision medicine. Here we propose a new method that models cell signaling using biological knowledge on signal transduction. The method recodes individual gene expression values (and/or gene mutations) into accurate measurements of changes in the activity of signaling circuits, which ultimately constitute high-throughput estimations of cell functionalities caused by gene activity within the pathway. Moreover, such estimations can be obtained either at cohort-level, in case/control comparisons, or personalized for individual patients. The accuracy of the method is demonstrated in an extensive analysis involving 5640 patients from 12 different cancer types. Circuit activity measurements not only have a high diagnostic value but also can be related to relevant disease outcomes such as survival, and can be used to assess therapeutic interventions.</p>
    </abstract>
    <kwd-group>
      <kwd>signaling pathway</kwd>
      <kwd>disease mechanism</kwd>
      <kwd>prognostic</kwd>
      <kwd>survival</kwd>
      <kwd>biomarker</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>INTRODUCTION</title>
    <p>Despite most phenotypic traits (including disease and drug response) are multi-genic, the vast majority of biomarkers in use are based on unique gene alterations (expression changes, mutations, etc.) Obviously, the determination of the status of a single gene is technically easier than multiple gene measurements. However, regardless of their extensive clinical utility, single gene biomarkers frequently lack any mechanistic link to the fundamental cellular processes responsible for disease progression or therapeutic response. Such processes are better understood as pathological alterations in the normal operation of functional modules caused by different combinations of gene perturbations (mutations or gene expression changes) rather than by alterations of a unique gene [<xref rid="R1" ref-type="bibr">1</xref>].</p>
    <p>Of particular interest are signaling pathways, a type of functional module known to play a key role in cancer origin and progression, as well as in other diseases. Consequently, analysis of the activity of signaling pathways should provide a more informative insight of cellular function. Actually, the recent demonstration that the inferred activity of the <italic>c-Jun N-terminal kinase</italic> pathway, shows significantly higher association to neuroblastoma patients’ mortality than the activity of their constituent genes (including <italic>MICN</italic>, the conventional neuroblastoma biomarker) [<xref rid="R2" ref-type="bibr">2</xref>] constitutes an elegant confirmation of this concept. In a similar example drug sensitivity is shown to be better predicted using probabilistic signaling pathway models than directly using gene activity values [<xref rid="R3" ref-type="bibr">3</xref>].</p>
    <p>However, conventional methods for pathway analysis, even the most sophisticated ones based on pathway topology, can only detect the existence of a significant level of gene activity within the pathway [<xref rid="R4" ref-type="bibr">4</xref>]. However, these methods ignore the obvious fact that many pathways are multifunctional and often trigger opposite functions (e.g. depending the receptor and the effector proteins involved in the transduction of the signal, the apoptosis pathway may trigger survival or cell death). Moreover, whether the level of gene activity detected by conventional methods actually triggers cell functionalities or not and, if so, what genes are the ultimate responsible for the resulting cell activity is something that must be determined <italic>a posteriori</italic>, usually by heuristic methods. Thus, pathway activity analysis (PAA) emerges as an alternative way of defining a new class of mechanistic biomarkers, whose activity is related to the molecular mechanisms that account for disease progression or drug response. However, capturing the aspects of the activity of the pathway that are really related to cell functionality is not trivial. This requires of an appropriate description of the elementary sub-pathways and an adequate computation of the individual contributions of gene activities to the actual activity of the sub-pathway. Different ways of computing activity scores for diverse sub-pathway definitions using gene expression values [<xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R8" ref-type="bibr">8</xref>], or even gene mutations [<xref rid="R9" ref-type="bibr">9</xref>], have been proposed (See Table <xref ref-type="table" rid="T1">1</xref>). However, in most of them sub-pathway definition is either disconnected, or only collaterally related, to the functional consequences of pathway activity (See Table <xref ref-type="table" rid="T1">1</xref>).</p>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <title>List of methods for Pathway Analysis</title>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="left" valign="middle" rowspan="1" colspan="1">Method</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Date</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Code</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Pathway modelled</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Entity modelled</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Input</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Output</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Comparison</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Loops</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">MinePath[<xref rid="R52" ref-type="bibr">52</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2015</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Web application<break/><ext-link ext-link-type="uri" xlink:href="http://minepath.org/">http://minepath.org/</ext-link></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value per pathway<break/>p-value per subpathway<break/>binary value per sample<break/>graphical visualization</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Qin et al.[<xref rid="R53" ref-type="bibr">53</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2015</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA<sup>b</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">12 cancer-related KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">signal quantification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Mutations<break/>CNVs<break/>Cancer drugs</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Pathway activity</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Personalized</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">subSPIA[<xref rid="R13" ref-type="bibr">13</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2015</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">R code</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">signal quantification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq (via SPIA in ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of DE per subpathway<break/>p-value of PF per subpathway<break/>global p-value (DE+PF)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Pathome[<xref rid="R54" ref-type="bibr">54</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2014</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">signal quantification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value per subpathway</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Pepe et al.[<xref rid="R55" ref-type="bibr">55</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2014</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">R code</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value per subpathway</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">ToPaSeq[<xref rid="R18" ref-type="bibr">18</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2014</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">graphite gene-gene networks<break/>user's pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">integrates other methods:<break/>TopologyGSA<break/>DEGraph<break/>Clipper<break/>SPIA<break/>TAPPA<break/>PRS<break/>PWEA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Depends on the method</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Depends on the method</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">DEAP[<xref rid="R12" ref-type="bibr">12</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2013</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">python code</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">user defined pathway structure</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">signal quantification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Score and p-value per pathway<break/>subgraph with the maximum absolute score</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">CliPPER[<xref rid="R5" ref-type="bibr">5</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2013</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">R package<break/>ToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">graphite gene-gene networks<break/>cliques<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value at pathway level<break/>Most affected subgraph per pathway<break/>Gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">GraphiteWeb[<xref rid="R56" ref-type="bibr">56</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2013</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Web application:<break/><ext-link ext-link-type="uri" xlink:href="http://graphiteweb.bio.unipd.it/Rpackage">http://graphiteweb.bio.unipd.it/Rpackage</ext-link></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways<break/>Reactome pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">integrates other methods:<break/>Hypergeometric test<break/>Global Test<break/>GSEA<break/>SPIA<break/>CliPPER</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Significant pathways<break/>Visualization of the pathways with nodes coloured according to their contribution to the analysis</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">TEAK[<xref rid="R57" ref-type="bibr">57</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2013</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Code @ Google (Windows and Mac)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">metabolism-orientedsubpathway identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ranked subpathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">PRS[<xref rid="R16" ref-type="bibr">16</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2012</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">graphite gene-gene networks (ToPASeq)<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">pathway identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value per pathway<break/>gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">DEGraph[<xref rid="R6" ref-type="bibr">6</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2012</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">R packageToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subgraphs of a large graph (branch-and-bound-like approach) graphite gene-gene networks (ToPASeq)<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of DE per subpathway<break/>p-value per pathway<break/>Gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Rivera et al.[<xref rid="R58" ref-type="bibr">58</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2012</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NetPathpathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of most perturbed subpathway</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Chen et al.[<xref rid="R59" ref-type="bibr">59</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2011</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value per subpathway<break/>p-value of key genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">PWEA[<xref rid="R17" ref-type="bibr">17</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2010</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Complete pathways (KEGG)<break/>graphite gene-gene networks (ToPASeq)<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">pathway identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of DE per pathway<break/>Gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">TopologyGSA[<xref rid="R14" ref-type="bibr">14</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2010</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Complete pathways (KEGG)<break/>Cliques<break/>graphite gene-gene networks (ToPASeq)<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNAseq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of DE per pathway<break/>Gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">DEGAS[<xref rid="R60" ref-type="bibr">60</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2010</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Java (Windows)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">KEGG pathways<break/>PPIs network</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">novel subpath identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">A subpathway per pathway</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">TAPPA[<xref rid="R15" ref-type="bibr">15</xref>]</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2007</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ToPASeq R package</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">graphite gene-gene networks (ToPASeq)<break/>user's pathways (via ToPASeq)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">pathway identification</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">MA<break/>RNASeq</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">p-value of DE per pathway<break/>Gene-level statistics for DE of genes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Two conditions</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">no</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>The first column (Method) contains the name or acronym of the method, if exists, otherwise, we refer to it as the fires author of the publication. The second column (Date) contains the publication date. The third column (code) informs on the availability of the code to run the method. The fourth column (Pathway modelled) indicates the pathway definition used in the method. The fifth column (Entity modelled) is the entity, within the pathway, used in the method (“subpath identification” methods obtain candidate sub-pathways usually by differential expression of its constituent genes, “signal quantification” methods provide, in addition, a quantification of the activation status of the sub-pathway). The sixth column (input) indicates the data type that inputs the method (MA: Expression Microarray; CNV: copy number variation; NA: not available). The seventh column (output) describes the results provided by the method. Some provide only a score (p-value, DE: differential expression matrix; PF: perturbation factor) for the whole pathway and other also provide scores for sub-pathways, that can be defined within the pathways in many different ways. The eight column (Comparison) indicates the type of comparison the method can deal with. It can be either a conventional two conditions (typically case/control) comparison or it can allow obtaining personalized results per individual. And the ninth column (Loops) indicates whether the method can handle loop structures in the topology of the sub-pathway analysed or not.</p>
      </table-wrap-foot>
    </table-wrap>
    <p>Here we propose a new method to estimate the activity within a pathway that uses biological knowledge on cell signaling to recode individual gene expression values (and/or gene mutations) into measurements that ultimately account for cell functionalities caused by the activity of the pathway. Specifically, we estimate the level of activity of stimulus-response sub-pathways (signaling circuits thereinafter) within signaling pathways, which ultimately trigger cell responses (e.g. proliferation, cell death, etc.) The activity values of these canonical circuits connected to the activation/deactivation of cell functionalities can be considered multigenic mechanistic biomarkers that can easily be related to phenotypes and provide direct clues to understand disease mechanisms and drug mechanisms of action (MoA). Therefore, we designate this method as canonical circuit activity analysis (CCAA).</p>
  </sec>
  <sec id="s2">
    <title>RESULTS</title>
    <sec id="s2_1">
      <title>Data pre-processing</title>
      <p>RNA-seq counts for 12 cancer types listed in Table <xref ref-type="table" rid="T2">2</xref> were downloaded from The Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>). In order to detect possible batch effects, principal component analysis (PCA) were calculated. The samples were plotted in the PCA representation by sequencing center, plate, cancer type and project. Only a clear batch effect by sequencing center and cancer was found (<xref ref-type="supplementary-material" rid="SD1">Figure S1A to S1E</xref>, upper panel), that was corrected by the application of the COMBAT [<xref rid="R10" ref-type="bibr">10</xref>] method (<xref ref-type="supplementary-material" rid="SD1">Figure S1F to S1J</xref>, lower panels). Then, the 538 samples of the Kidney renal clear cell carcinoma (KIRC) dataset were further normalized using TMM [<xref rid="R11" ref-type="bibr">11</xref>] to account for RNA composition bias. Normalized data were used as input for the CCAA method.</p>
      <table-wrap id="T2" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <title>Cancers used in this study with the number of samples sequenced of both tumour biopsy and normal adjacent tissue</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th align="left" valign="middle" rowspan="1" colspan="1">TCGA Identifier</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Cancer</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Primary tumor</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Normal adjacent tissue</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Ref.</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">BLCA</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Bladder Urothelial Carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">301</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">17</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R29" ref-type="bibr">29</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">BRCA</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Breast invasive carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1057</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">113</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R30" ref-type="bibr">30</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">COAD</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Colon adenocarcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">451</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">41</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R31" ref-type="bibr">31</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">HNSC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Head and Neck squamous cell carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">480</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">42</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R32" ref-type="bibr">32</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">KIRC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Kidney renal clear cell carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">526</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">72</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R19" ref-type="bibr">19</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">KIRP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Kidney renal papillary cell carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">222</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">32</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R33" ref-type="bibr">33</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">LIHC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Liver hepatocellular carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">294</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">48</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">LUAD</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Lung adenocarcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">486</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">55</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R34" ref-type="bibr">34</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">LUSC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Lung squamous cell carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">428</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">45</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R35" ref-type="bibr">35</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">PRAD</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Prostate adenocarcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">379</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">52</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">THCA</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Thyroid carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">500</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">58</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R37" ref-type="bibr">37</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle" rowspan="1" colspan="1">UCEC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Uterine Corpus Endometrial Carcinoma</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">516</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">23</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="R38" ref-type="bibr">38</xref>]</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Comparison of performances of the different methods for defining pathways and calculating its activity</title>
          <p>CCAA is compared to DEAP [<xref rid="R12" ref-type="bibr">12</xref>], subSPIA [<xref rid="R13" ref-type="bibr">13</xref>], using their own software, and topologyGSA [<xref rid="R14" ref-type="bibr">14</xref>], DEGraph [<xref rid="R6" ref-type="bibr">6</xref>], clipper [<xref rid="R5" ref-type="bibr">5</xref>], TAPPA [<xref rid="R15" ref-type="bibr">15</xref>], PRS [<xref rid="R16" ref-type="bibr">16</xref>], PWEA [<xref rid="R17" ref-type="bibr">17</xref>], using the implementation available in the topaseq package [<xref rid="R18" ref-type="bibr">18</xref>]. The true positive rate has been estimated averaging the proportion of significant cancer KEGG pathways (Table <xref ref-type="table" rid="T3">3</xref>) across the 12 cancers analyzed and is represented in the Y axis. Vertical bars in each point represent 1 SD of the true positive rate for the corresponding method. The false positive rate was estimated from 100 comparisons of groups (N=25) of identical individuals, randomly sampled from each cancer. The results obtained in the 12 cancers are used to obtain a mean value and an error. The X axis represents 1- the false positive rate. Horizontal bars represent in each point represent 1 SD of the false positive rate for the corresponding method.</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g001"/>
      </fig>
    </sec>
    <sec id="s2_2">
      <title>Estimation of the specificity of the CCAA method</title>
      <p>In order to estimate the false positive rate, we generated different sets of indistinguishable samples that were randomly divided into two groups which were compared to try to find differentially activated circuits. Given that the compared groups are composed of the same type of individuals, any significant difference in sub-pathway activity found in the comparisons would be considered a false positive of the method. Real and simulated samples were used for this purpose (see Methods) and the ratio of false positives was always very low, far below the conventional alpha value of 0.05 (see <xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>).</p>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>Circos plot that summarises the relationships between effectors within pathways and the functions triggered by them</title>
          <p>Only cancer KEGG pathways (Table <xref ref-type="table" rid="T3">3</xref>) related to functions significantly related to survival are represented here. On the right side appear the effector circuits grouped according to the pathway they belong to. There is a histogram per pathway that represents the proportion of effector pathways upregulated (red), downregulated (blue) and dysregulated in both directions (yellow). On the left side of the circo appear the functions triggered by the effector circuits divided into those which are significant when are up-regulated (red), when are down-regulated (blue) or when both situations occur (yellow). For each function there is a band that indicates the prognostic of its deregulation, which can be good (green) or bad (grey).</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g002"/>
      </fig>
    </sec>
    <sec id="s2_3">
      <title>Estimation of the sensitivity of the CCAA method</title>
      <p>In order to obtain an estimation the true positive rate of the CCAA method, we compared cancer samples versus the corresponding healthy tissue in a series of contrasts with different sizes (N=50,100,200 and 400 samples; see Methods) from which we expect differences in cancer-associated pathways. Two different cancer types, KIRC and BRCA, were used to avoid biases derived from using only a specific type of cancer. We have used two definitions of cancer associated pathways, one of them taken from KEGG (composed of 14 pathways belonging to the Cancer pathways category, see Table <xref ref-type="table" rid="T3">3</xref>), and the other one that contains 49 pathways curated by experts (Table <xref ref-type="table" rid="T4">4</xref>). <xref ref-type="supplementary-material" rid="SD1">Figure S3</xref> shows how, except in the case of very small datasets in which the statistical power of the method for detecting significant differences is limited, the proposed CCAA methodology clearly identifies significant changes for both cancers in the two cancer pathway definitions used.</p>
      <table-wrap id="T3" orientation="portrait" position="float">
        <label>Table 3</label>
        <caption>
          <title>KEGG cancer pathways</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th align="left" valign="middle" rowspan="1" colspan="1">KEGG identifier</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Name</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04010</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">MAPK signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04310</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Wnt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04350</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">TGF-beta signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04370</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">VEGF signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04630</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Jak-STAT signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04024</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">cAMP signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04151</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PI3K-Akt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04150</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">mTOR signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04110</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell cycle</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04210</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Apoptosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04115</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">p53 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04510</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Focal adhesion</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04520</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adherens junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa03320</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T4" orientation="portrait" position="float">
        <label>Table 4</label>
        <caption>
          <title>Curated cancer pathways</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th align="left" valign="middle" rowspan="1" colspan="1">KEGG identifier</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Name</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04014</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ras signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04015</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Rap1 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04010</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">MAPK signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04012</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">ErbB signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04310</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Wnt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04330</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Notch signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04340</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hedgehog signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04350</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">TGF-beta signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04390</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hippo signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04370</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">VEGF signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04630</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Jak-STAT signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04064</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">NF-kappa B signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04668</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">TNF signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04066</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">HIF-1 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04068</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">FoxO signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04020</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Calcium signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04024</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">cAMP signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04022</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">cGMP-PKG signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04151</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PI3K-Akt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04152</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">AMPK signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04150</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">mTOR signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04110</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell cycle</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04114</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Oocyte meiosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04210</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Apoptosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04115</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">p53 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04510</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Focal adhesion</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04520</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adherens junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04530</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Tight junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04540</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gap junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04611</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Platelet activation</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04620</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Toll-like receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04621</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">NOD-like receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04650</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Natural killer cell mediated cytotoxicity</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04660</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">T cell receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04662</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">B cell receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04670</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Leukocyte transendothelial migration</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04062</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Chemokine signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04910</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Insulin signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04920</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adipocytokine signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa03320</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04912</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">GnRH signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04915</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Estrogen signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04914</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Progesterone-mediated oocyte maturation</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04919</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Thyroid hormone signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04916</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Melanogenesis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05200</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Pathways in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05231</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Choline metabolism in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05202</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Transcriptional misregulation in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05205</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Proteoglycans in cancer</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Increase of <italic>DNA replication</italic> activity is related to bad prognostic</title>
          <p>Effector nodes in two pathways trigger <italic>DNA replication</italic> in KIRC, as detected by the Hipathia program (<ext-link ext-link-type="uri" xlink:href="http://hipathia.babelomics.org">http://hipathia.babelomics.org</ext-link>). Genes in red represent genes upregulated in the cancer with respect to the corresponding normal tissue; genes in blue represent downregulated genes and genes with no color were not differentially expressed. <bold>A</bold>. Cell Cycle signaling pathway with three effector circuits highlighted, one of them ending in the node containing proteins <italic>CDC6, ORC3, ORC5, ORC4, ORC2, ORC1</italic> and <italic>ORC6</italic>, the second one ending in node with proteins <italic>CDC45, MCM7, MCM6, MCM5, MCM4, MCM3</italic> and <italic>MCM2</italic> and the last one ending in node with proteins <italic>ORC3, ORC5, ORC4, ORC2, ORC1, ORC6, MCM7, MCM6, MCM5, MCM4, MCM3</italic> and <italic>MCM2</italic>. <bold>B</bold>. p53 signaling pathway with the effector circuit ending in protein <italic>RRM2B</italic> highlighted. <bold>C</bold>. Survival Kaplan-Meier (K-M) curves obtained for Uniprot function <italic>DNA replication</italic>.</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g003"/>
      </fig>
    </sec>
    <sec id="s2_4">
      <title>Comparison to other available PAA methods</title>
      <p>The performance of our method was compared to other PAA methods that provide different definitions of sub-pathways and distinct algorithms to calculate a score for them. From the list in (Table <xref ref-type="table" rid="T1">1</xref>) we used eight methods that satisfy two basic conditions: they can be applied to RNA-seq data and there is software available for running them. These are: DEAP [<xref rid="R12" ref-type="bibr">12</xref>], subSPIA [<xref rid="R13" ref-type="bibr">13</xref>], using their own software, and topologyGSA [<xref rid="R14" ref-type="bibr">14</xref>], DEGraph [<xref rid="R6" ref-type="bibr">6</xref>], clipper [<xref rid="R5" ref-type="bibr">5</xref>], TAPPA [<xref rid="R15" ref-type="bibr">15</xref>], PRS [<xref rid="R16" ref-type="bibr">16</xref>], PWEA [<xref rid="R17" ref-type="bibr">17</xref>], using the implementation available in the topaseq package [<xref rid="R18" ref-type="bibr">18</xref>]. Figure <xref ref-type="fig" rid="F1">1</xref> represents the true positive and true negative ratios obtained for any of the methods compared (See Methods). While most of the pathway activity definitions are reasonably specific, with true negative ratios over 95% (except clipper, topologyGSA and PWEA, probably because they define sub-pathways unconnected with cell functionality), the sensitivity is generally low (in most cases below 50%). When the curated list of cancer pathways (see Table <xref ref-type="table" rid="T4">4</xref>) is used, the performance of some methods improves but still, the sensibility is in general low (clearly below 75%, see Figure <xref ref-type="fig" rid="F4">4</xref>).</p>
      <fig id="F4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>DNA replication is triggered by the same circuits in KIRC and BRCA, but using a different pattern of gene activation</title>
          <p>The Hipathia program (<ext-link ext-link-type="uri" xlink:href="http://hipathia.babelomics.org">http://hipathia.babelomics.org</ext-link>) detected a total of four effector circuits in two pathways, Cell Cycle and P53 signaling, that are used by both cancers to trigger DNA replication. Arrows in red represent activated circuits. Genes in red represent genes upregulated in the cancer with respect to the corresponding normal tissue; genes in blue represent downregulated genes and genes with no color were not differentially expressed. Squares at the end of the circuit represent the cell functions triggered by the circuits. <bold>A</bold>. Cell Cycle signaling pathway in KIRC with three effector circuits activated (highlighted), one of them ending in the node containing proteins <italic>CDC6, ORC3, ORC5, ORC4, ORC2, ORC1</italic> and <italic>ORC6</italic>, the second one ending in node with proteins <italic>CDC45, MCM7, MCM6, MCM5, MCM4, MCM3</italic> and <italic>MCM2</italic> and the last one ending in node with proteins <italic>ORC3, ORC5, ORC4, ORC2, ORC1, ORC6, MCM7, MCM6, MCM5, MCM4, MCM3</italic> and <italic>MCM2</italic>. <bold>B</bold>. P53 signaling pathway in BRCA with the effector circuit ending in protein <italic>RRM2B</italic> highlighted. <bold>C</bold>. Cell Cycle pathway in BRCA with the same effector circuits activated that in KIRC, but using a different set of gene activations. <bold>D</bold>. P53 signaling pathway in BRCA with the same effector circuit activated that in KIRC, but using a different set of gene activations.</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g004"/>
      </fig>
      <p>From the technical standpoint, the CCAA method can handle loops in the pathway topology, a feature absent in most PAA methods (see Table <xref ref-type="table" rid="T1">1</xref>) allowing a more comprehensive description of the circuit activity.</p>
      <p>These results demonstrates that all the PAA methods analyzed, except ours, are not properly capturing the biological signal and consequently failed to detect cancer pathway activities when cancer and normal tissues were compared, across twelve different cancer types.</p>
    </sec>
    <sec id="s2_5">
      <title>A case example with kidney renal clear cell carcinoma</title>
      <p>To demonstrate the utility of this approach in defining the activity of canonical signaling circuits as highly reliable mechanistic biomarkers that, in addition, account for important disease outcomes such as survival, kidney renal clear cell carcinoma (KIRC) [<xref rid="R19" ref-type="bibr">19</xref>] data was used. In addition, survival data available on patients were used to demonstrate that the activity of many of the selected circuits is significantly related to the prognostic of the disease.</p>
      <p>Firstly, 526 cancer samples were compared against the 72 available controls of normal kidney tissue adjacent to the primary tumors (See Table <xref ref-type="table" rid="T2">2</xref>). The comparison was made at the level of canonical circuits (see Methods), effector circuits and functions (using both Uniprot and GO annotations). As expectable, given the large number of differentially expressed genes between the cancer and the healthy tissue [<xref rid="R19" ref-type="bibr">19</xref>], a large number of signaling circuits present a significant differential activation between the compared conditions (4966 with a FDR-adjusted p-value &lt; 0.01; See <xref ref-type="supplementary-material" rid="SD2">Table S1</xref>). Focusing on effector circuits, this signaling interplay is reduced to 870 significant changes in the intensity of signal reception (with a FDR-adjusted p-value &lt; 0.01; See <xref ref-type="supplementary-material" rid="SD3">Table S2</xref>). These effector nodes significantly trigger 71 cell functionalities (according to Uniprot general definitions, see <xref ref-type="supplementary-material" rid="SD4">Table S3</xref>, which summarize 320 more detailed cell functionalities according to GO definitions, see <xref ref-type="supplementary-material" rid="SD5">Table S4</xref>; both with a FDR-adjusted p-value &lt; 0.01). Figure <xref ref-type="fig" rid="F2">2</xref> summarizes the different functions dysregulated by circuits in different KEGG cancer pathways (see Table <xref ref-type="table" rid="T3">3</xref>) and the corresponding impact on patient’s survival. <xref ref-type="supplementary-material" rid="SD1">Figure S5</xref> expands this summary to the set of curated cancer pathways listed in Table <xref ref-type="table" rid="T4">4</xref>. Although some functionalities are quite general descriptions of cellular biological processes and others can be consequences of the extreme deregulation process occurring in cancer cells, a considerable number of them can be clearly linked to tumorigenic processes and can easily be mapped to cancer hallmarks [<xref rid="R20" ref-type="bibr">20</xref>].</p>
      <fig id="F5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Schema that illustrates the relationship between circuits, effector circuits and functions</title>
          <p>Left: signaling circuits, which are canonical sub-pathways that transmit signals from a unique receptor to a unique effector node. Center: effector circuits that represent the combined activity of all the signals that converge into a unique effector node. Right: functional activity that represents the combined effect of the signal received by all the effectors that trigger a particular cell function.</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g005"/>
      </fig>
    </sec>
    <sec id="s2_6">
      <title>Circuits that trigger cancer hallmarks determine patient survival</title>
      <p>Since survival data was among the clinical information available survival analysis of the significant effector circuits, and functions listed in <xref ref-type="supplementary-material" rid="SD2">Tables S1</xref>, <xref ref-type="supplementary-material" rid="SD3">S2</xref>, <xref ref-type="supplementary-material" rid="SD4">S3</xref> and <xref ref-type="supplementary-material" rid="SD5">S4</xref>) was carried out. This analysis provides an independent validation of the involvement of several cell functionalities, as well as several signaling circuits that trigger them, in cancer pathogenesis.</p>
      <p>Survival analysis discovered a total of 310 effector circuits whose dysregulation is significantly associated to good or poor cancer prognostic (<xref ref-type="supplementary-material" rid="SD6">Table S5</xref>). These circuits trigger a total of 31 general cell functionalities, according to Uniprot definitions (<xref ref-type="supplementary-material" rid="SD7">Table S6</xref>) that can be expanded to 108 more detailed GO definitions (<xref ref-type="supplementary-material" rid="SD8">Table S7</xref>), which are significantly related to patient’s survival.</p>
      <table-wrap id="T5" orientation="portrait" position="float">
        <label>Table 5</label>
        <caption>
          <title>Circuits which are most significantly associated to survival than their constituent genes</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th align="left" valign="middle" rowspan="1" colspan="1">Circuit</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Circuit Status</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Adjusted p-value</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Gene</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">GeneStatus</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Adjusted p-value</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">General functional category</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Function Status</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Adjusted p-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Cell cycle: CDC45 MCM7 MCM6 MCM5 MCM4 MCM3 MCM2</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.08E-11</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CDC7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.68E-07</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DNA replication</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.94E-08</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Cell cycle: ORC3 ORC5 ORC4 ORC2 ORC1 ORC6 MCM7 MCM6 MCM5 MCM4 MCM3 MCM2</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.26E-09</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CDC7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.68E-07</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DNA replication</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.94E-08</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Glucagon signaling pathway: G6PC</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.57E-06</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PPARGC1A</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.97E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gluconeogenesis</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">8.96E-06</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Glucagon signaling pathway: PCK1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.31E-07</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PPARGC1A</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.97E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gluconeogenesis</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">8.96E-06</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway: PCK1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.75E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PCK1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.39E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gluconeogenesis</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">8.96E-06</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway: LPL</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00095506</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">LPL</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00509595</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Lipid metabolism</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.59E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway: CYP7A1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00209578</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">RXRA</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00577708</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Lipid metabolism</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.59E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Leukocyte transendothelial migration: CDH5</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.81E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CDH5</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.14E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Adherens junction: CTNNA1 CTNNB1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.91E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CTNNA1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00016432</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway: CD36</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.46E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CD36</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00030595</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Proteoglycans in cancer: ITGAV*</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.81E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">ITGAV</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.0006759</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Leukocyte transendothelial migration: PECAM1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00063309</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PECAM1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.0009573</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Adherens junction: CDH1*</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00637905</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CDH1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.0078199</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell adhesion</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.46E-05</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">AMPK signaling pathway: CCNA2</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.04E-12</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">STRADA</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">UP</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.34E-07</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell division</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00152171</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Tight junction: PARD6A MPP5</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.45E-05</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">CDC42</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00011452</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell division</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">DOWN</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.00152171</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>The circuits are defined as the pathway to which it belongs to and the final effector node that triggers the function. The status for circuits, genes and functions are UP or DOWN depending on the respective increase or decrease of their activities when the cancer is compared to the normal tissue. The gene column contains the gene with the best association to survival (lower adjusted p-value) among all the genes in the corresponding circuit.</p>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T6" orientation="portrait" position="float">
        <label>Table 6</label>
        <caption>
          <title>KEGG pathways modeled in this study</title>
        </caption>
        <table frame="box" rules="all">
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">
                <bold>KEGG identifier</bold>
              </td>
              <td align="center" valign="middle" rowspan="1" colspan="1">
                <bold>Name</bold>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04014</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Ras signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04015</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Rap1 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04010</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">MAPK signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04012</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">ErbB signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04310</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Wnt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04330</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Notch signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04340</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hedgehog signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04350</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">TGF-beta signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04390</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hippo signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04370</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">VEGF signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04630</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Jak-STAT signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04064</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">NF-kappa B signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04668</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">TNF signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04066</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">HIF-1 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04068</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">FoxO signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04020</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Calcium signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04071</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Sphingolipid signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04024</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">cAMP signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04022</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">cGMP-PKG signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04151</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PI3K-Akt signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04152</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">AMPK signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04150</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">mTOR signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04110</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Cell cycle</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04114</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Oocyte meiosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04210</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Apoptosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04115</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">p53 signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04510</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Focal adhesion</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04520</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adherens junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04530</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Tight junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04540</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gap junction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04611</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Platelet activation</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04620</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Toll-like receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04621</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">NOD-like receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04622</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">RIG-I-like receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04650</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Natural killer cell mediated cytotoxicity</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04660</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">T cell receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04662</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">B cell receptor signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04664</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Fc epsilon RI signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04666</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Fc gamma R-mediated phagocytosis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04670</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Leukocyte transendothelial migration</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04062</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Chemokine signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04910</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Insulin signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04922</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Glucagon signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04920</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adipocytokine signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa03320</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">PPAR signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04912</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">GnRH signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04915</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Estrogen signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04914</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Progesterone-mediated oocyte maturation</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04921</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Oxytocin signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04919</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Thyroid hormone signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04916</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Melanogenesis</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04261</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Adrenergic signaling in cardiomyocytes</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04270</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Vascular smooth muscle contraction</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04722</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Neurotrophin signaling pathway</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05200</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Pathways in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05231</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Choline metabolism in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05202</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Transcriptional misregulation in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05205</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Proteoglycans in cancer</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa04971</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Gastric acid secretion</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">hsa05160</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis C</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The main cancer hallmark is sustained proliferation [<xref rid="R20" ref-type="bibr">20</xref>]. A clear example of effector circuit related to this hallmark is the <italic>CCNA2</italic>, from the AMPK signaling pathway, whose high levels of activity are significantly associated to bad prognostic in the patients in which triggers the <italic>Cell division</italic> function (<xref ref-type="supplementary-material" rid="SD1">Figure S6A</xref>). Actually, there is a significant increase in the activity of the <italic>CCNA2</italic> effector circuit as cancer stage progresses (<xref ref-type="supplementary-material" rid="SD1">Figure S6C</xref>). In fact, dysregulated genes were recently identified in this sub-pathway that might be potential biological markers and processes for treatment and etiology mechanism in KIRC [<xref rid="R21" ref-type="bibr">21</xref>]. Another similar example is the effector circuit ending in node <italic>CDK2</italic>, <italic>CCNE1</italic> from the p53 signaling pathway, and triggering the <italic>Cell cycle</italic> function, whose increased activity is significantly associated to bad prognostic in KIRC patients (<xref ref-type="supplementary-material" rid="SD1">Figure S7A and S7B</xref>). In addition, there is a significant increase in the activity of the <italic>CDK2</italic>, <italic>CCNE1</italic> effector circuit as cancer stage progresses (<xref ref-type="supplementary-material" rid="SD1">Figure S7C</xref>). Recently, <italic>CDK2</italic>, <italic>CCNE1</italic> genes were described as cancer prognostic factors [<xref rid="R22" ref-type="bibr">22</xref>]. When the association is carried out at the function level, there are two Uniprot functions (<xref ref-type="supplementary-material" rid="SD7">Table S6</xref>) representative of sustained proliferation hallmark: <italic>Mitosis</italic> (FDR-adjusted p-value 1.7×10<sup>−12</sup>) and <italic>DNA replication</italic> (FDR-adjusted p-value=5.9×10<sup>−8</sup>), whose upregulation is significantly associated to bad prognostic (See <xref ref-type="supplementary-material" rid="SD1">Figures S7A and S7B</xref>).</p>
      <fig id="F6" orientation="portrait" position="float">
        <label>Figure 6</label>
        <caption>
          <title>Schematic representation of the signal propagation algorithm used</title>
          <p>Upper part: the three types of activity transmitted: left) the combination of two activations, center) the combination of an activation and an inhibition and right) the combination of two inhibitions. Central part: the normalized values of gene expression are assigned to the corresponding nodes in the circuits. Lower part: the signal starts with a value of 1 in the receptor node A and is propagated by multiplying the weights assigned to each node in the central part following the rules depicted in the upper part.</p>
        </caption>
        <graphic xlink:href="oncotarget-08-5160-g006"/>
      </fig>
      <p>Another cancer hallmark is the activation of metastasis and invasion, favored when the Uniprot function <italic>Cell adhesion</italic> decreases. <xref ref-type="supplementary-material" rid="SD1">Figure S7C</xref> depicts a clear association between the downregulation of <italic>Cell adhesion</italic> and the poorer prognostic in patients (FDR-adjusted p-value=4.4×10<sup>−5</sup>).</p>
      <p>The third classical cancer hallmark in solid tumors is the induction of angiogenesis. <italic>Angiogenesis</italic> appears as significantly associated to survival in both Uniprot and GO annotations (<xref ref-type="supplementary-material" rid="SD7">Tables S6</xref> and <xref ref-type="supplementary-material" rid="SD8">S7</xref>). <xref ref-type="supplementary-material" rid="SD1">Figure S8D</xref> depicts a significant relationship between the upregulation of <italic>Positive regulation of angiogenesis</italic> and higher patient’s mortality (FDR-adjusted p-value=2.9×10<sup>−2</sup>). Actually, the downregulation of the opposite term, <italic>Negative regulation of angiogenesis</italic>, is also associated to bad prognostic, as expected, although with marginal significance (FDR-adjusted p-value=0.055).</p>
      <p>Finally, the CCAA method also detects the well-known Warburg effect, the observed increased uptake and utilization of glucose, documented in many human tumor types [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R23" ref-type="bibr">23</xref>]. Our functional analysis clearly predicts a bad prognostic for reduced <italic>gluconeogenesis</italic> (FDR-adjusted p-value = 8.96×10<sup>−6</sup>, see <xref ref-type="supplementary-material" rid="SD7">Table S6</xref>). Actually, it has recently been suggested a novel mechanism of cancer cell death by increasing the gluconeogenesis pathway activity via mTOR inhibitors [<xref rid="R24" ref-type="bibr">24</xref>].</p>
      <p>In addition, the CCAA method detects several terms whose perturbed activity seem a consequence of the dedifferentiation process that occur in kidney cancer cells, such as the down-activation of <italic>Sodium/potassium transport</italic> (FDR-adjusted p-value=2.95×10<sup>−9</sup>), Sodium transport (FDR-adjusted p-value=8.96×10<sup>−6</sup>) and, the general term Transport (FDR-adjusted p-value= 6.52×10<sup>−5</sup>) (see <xref ref-type="supplementary-material" rid="SD7">Table S6</xref>).</p>
      <p>Moreover, in some specific circuits triggering cancer hallmarks the association of the activity of the circuit to the mortality of the patient resulted to be higher than the individual association of any of the genes that form the circuit. Table <xref ref-type="table" rid="T5">5</xref> lists some circuits along with the general functional categories clearly related to proliferation (DNA replication and Cell division), metastasis (Cell adhesion) and Warburg effect (Gluconeogenesis and Lipid metabolism). Our results show that the initial observation made for the <italic>c-Jun N-terminal kinase</italic> pathway as a superior predictor of prognostic in neuroblastoma [<xref rid="R2" ref-type="bibr">2</xref>] can be generalized to other circuits that trigger cell functionalities related to cancer hallmarks.</p>
    </sec>
    <sec id="s2_7">
      <title>Cancer progression driven by specific circuits instead of specific genes</title>
      <p>An additional advantage of using CCAA is that the signaling circuits that trigger the functions in this particular cancer can be easily traced back. <italic>DNA replication</italic> is an example of function that can easily be mapped to the <italic>sustained proliferative signaling</italic> cancer hallmark [<xref rid="R20" ref-type="bibr">20</xref>]. The increase in the activity of this function is significantly related with poor prognostic (FDR-adjusted p-value=5.94×10<sup>−8</sup>). Three effector circuits belonging to the <italic>Cell cycle</italic> and the <italic>p53 pathways</italic> (See Figure <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="supplementary-material" rid="SD7">Table S6</xref>) are the ultimate responsible for the activation of this function. Moreover, it has been described that dysregulation of different genes within the same pathway may have a similar impact on downstream pathway function [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. Figure <xref ref-type="fig" rid="F4">4</xref> demonstrates how the CCAA method can detect the same functional consequence (activation of DNA replication) caused by distinct, non-recurrent, differential gene expression patterns in two different cancers (BRCA and KIRC). The detection of the specific circuits and the particular gene activities involved in the tumorigenesis process has enormous therapeutic implications.</p>
    </sec>
  </sec>
  <sec id="s3">
    <title>DISCUSSION</title>
    <p>Models of pathway activity bridge the gap between conventional approaches based on single-gene biomarkers, or functional enrichment methods, and more realistic, model-based approaches. Models use biological knowledge available on relevant biological modules (such as signaling pathways) to explain how their perturbations ultimately cause diseases or responses to treatments. Therefore, such perturbations (initially gene expression changes) can be related to disease mechanisms or drug MoAs [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>].</p>
    <p>A unique feature of the CCAA method is that, if the analysis is made at the level of cell functionality, the changes in the activity detected can be traced back to the circuits in order to discover which ones are triggering the action and what genes are the ultimate causative agents of such functional activity changes. Therefore, the resulting models can be used to suggest and predict the effect of interventions (KOs, drugs or over-expressions) on specific genes in the circuits so as to find suitable clinical targets, predict side effects, speculate off-target activities, etc. Depending on the scenario studied, such interventions can be more general or more personalized.</p>
    <p>Another relevant feature missing in the rest of PAA methods (Table <xref ref-type="table" rid="T1">1</xref>) is the possibility of obtaining individual values of circuit, effector or function activities for each sample. This opens the door to obtaining patient-specific personalized functional profiles connected to the corresponding signaling circuits.</p>
    <p>Since clinical data are available at the TCGA repository, we were able to find significant associations of specific pathway activities to patient survival, proving thus the validity of PAA methodology to capture cell processes involved in disease outcome.</p>
    <p>Finally, it is worth mentioning that the integration of information on protein functionality in the model, if it is available, is straightforward. (See Methods for details). Other omic data (methylomics data, Copy Number Variation, etc.) could also be easily introduced in the model providing they could be coded as proxies of presence and/or integrity of the protein.</p>
  </sec>
  <sec sec-type="methods" id="s4">
    <title>MATERIALS AND METHODS</title>
    <sec id="s4_1">
      <title>Data source and processing</title>
      <p>We used 12 cancer types from The Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>) in which RNA-seq counts for healthy control samples were available in addition to the cancer samples: Bladder Urothelial Carcinoma (BLCA) [<xref rid="R29" ref-type="bibr">29</xref>], Breast invasive carcinoma (BRCA) [<xref rid="R30" ref-type="bibr">30</xref>], Colon adenocarcinoma (COAD) [<xref rid="R31" ref-type="bibr">31</xref>], Head and Neck squamous cell carcinoma (HNSC) [<xref rid="R32" ref-type="bibr">32</xref>], Kidney renal clear cell carcinoma (KIRC) [<xref rid="R19" ref-type="bibr">19</xref>], Kidney renal papillary cell carcinoma (KIRP) [<xref rid="R33" ref-type="bibr">33</xref>], Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD) [<xref rid="R34" ref-type="bibr">34</xref>], Lung squamous cell carcinoma (LUSC) [<xref rid="R35" ref-type="bibr">35</xref>], Prostate adenocarcinoma (PRAD) [<xref rid="R36" ref-type="bibr">36</xref>], Thyroid carcinoma (THCA) [<xref rid="R37" ref-type="bibr">37</xref>] and Uterine Corpus Endometrial Carcinoma (UCEC) [<xref rid="R38" ref-type="bibr">38</xref>] (Table <xref ref-type="table" rid="T2">2</xref>).</p>
      <p>Since TCGA cancer data has different origins and underwent different management processes, non-biological experimental variations (batch effect) associated to Genome Characterization Center (GCC) and plate ID must be removed from the RNA-seq data. The COMBAT method [<xref rid="R10" ref-type="bibr">10</xref>] was used for this purpose. This method estimates the location and scale model parameters that represent batch effects and shrink them towards the overall mean of the batch effect estimates. Then, these estimates are used to adjust the data for batch effects. Then, we applied the trimmed mean of M-values normalization method (TMM) method [<xref rid="R11" ref-type="bibr">11</xref>] for data normalization. TMM is a very efficient normalization method that corrects a well-known artifact derived from the RNA-Seq technology: the RNA-composition bias. When comparing two different samples, the number of read counts of an equally expressed gene may vary depending on the level of expression of the other genes due to the fact that the library depth is fixed. The read counts of a gene represent the proportion of the gene with respect to the total RNA production of the sample, but this proportion is not a quantitative number which can be compared if the total RNA production is different between samples. TMM normalization estimates the ratio of RNA production between samples with a weighted trimmed mean of the log expression ratios (trimmed mean of M values or TMM). Then it uses this estimation to modify the observed library size of a sample to a comparable library size which follows the proportion of RNA production between the samples. The resulting normalized values were entered to the pathway activity analysis method.</p>
    </sec>
    <sec id="s4_2">
      <title>Modelling framework</title>
      <p>Modelling of pathway activity requires initially of a formal description of the relationships between proteins within the pathway, which can be taken from different pathway repositories. Here KEGG pathways [<xref rid="R39" ref-type="bibr">39</xref>] are used, but any other repository could be used instead, as Reactome [<xref rid="R40" ref-type="bibr">40</xref>] or others. It also requires of a way to estimate the activation status of each protein, which accounts for the intensity of signal they can transmit along the pathway.</p>
      <p>A total of 60 KEGG pathways (see Table <xref ref-type="table" rid="T6">6</xref>), which include the main KEGG categories related to signaling, such as: signal transduction pathways, Signaling molecules and interaction pathways, Cell growth and death, Cell Communication, endocrine system and immune system, as well as some other related pathways are used in this modelling framework. This selection of pathways includes a total of 2212 gene products that participate in 3379 nodes. It must be noted that any gene product can participate in more than one node (even in different pathways) and a node can contain more than one gene product. Pathways are directed networks in which nodes (composed by one or more proteins) relate to each other by edges. Only two different kinds of relation between nodes are considered: activations and inhibitions. In KEGG pathways, edges define different types of protein interactions that include phosphorilations, ubiquitinations, glycosilations, etc., but they include a label indicating if they act as activations or inhibitions.</p>
      <p>In order to transmit the signal along the pathway, a protein needs: first, to be present and functional, and second, to be activated by other protein. Preferably, the activity of the proteins should be inferred from (phospho) proteomic and chemoproteomic experiments [<xref rid="R41" ref-type="bibr">41</xref>], however, the production of these types of data still results relatively complex [<xref rid="R42" ref-type="bibr">42</xref>]. Instead, an extensively used approach is taking the presence of the mRNA corresponding to the protein as a proxy for the presence of the protein [<xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R43" ref-type="bibr">43</xref>]. Therefore, the presence of the mRNAs corresponding to the proteins present in the pathway is quantified as a normalized value between 0 and 1. Second, a value of signal intensity transmitted through a protein is computed, taking into account the level of expression of the corresponding mRNA and the intensity of the signal arriving to it. The net value of signal transmitted across the pathway corresponds to the signal values transmitted by the last proteins of the pathway that ultimately trigger the cell functions activated by the pathway.</p>
    </sec>
    <sec id="s4_3">
      <title>Decomposing pathways into circuits</title>
      <p>Pathways are represented by directed graphs, which connect input (receptor) nodes to output (effector) nodes. The signal arrives to an initial input node and is transmitted along the pathway following the direction of the interactions until it reaches an output node that triggers an action within the cell. Thus, from different input nodes the signal may follow different routes along the pathway to reach different output nodes. Within this modelling context, a canonical circuit is defined as any possible route the signal can traverse to be transmitted from a particular input to a specific output node (see Figure <xref ref-type="fig" rid="F5">5</xref>, left).</p>
      <p>Output nodes at the end of canonical are the ultimate responsible to carry out the action the signal is intended to trigger in the cell. Then, from a functional viewpoint, an effector circuit can be defined as a higher-level signaling entity composed by the collection of all the canonical circuits ending in an unique output (effector) node (see Figure <xref ref-type="fig" rid="F5">5</xref>, center). When applied to effector circuits, the method returns the joint intensity of the signal arriving to the corresponding effector node.</p>
      <p>A total of 6101 canonical circuits and 1038 effector circuits can be defined in the 60 pathways modelled.</p>
    </sec>
    <sec id="s4_4">
      <title>Computing the circuit activity</title>
      <p>The methodology proposed uses gene expression values as proxies of protein presence values, and consequently of potential protein activation values [<xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R42" ref-type="bibr">42</xref>–<xref rid="R44" ref-type="bibr">44</xref>]. The inferred protein activity values are then transformed into node activity values using the information on node composition taken from KEGG. KEGG defines two types of nodes: plain nodes, which may contain one or more proteins, whose value is summarized as the percentile 90 of the values of the proteins contained in it, and complex nodes, for which the minimum value of the proteins contained (the limiting component of the complex), is taken as the node activity value.</p>
      <p>Once the node activity values have been estimated, the computation of the signal intensity across the different circuits of the pathways is performed by means of an iterative algorithm beginning in the input nodes of each circuit. In order to initialize the circuit signal we assume an incoming signal value of 1 in the input nodes of any circuit. Then, for each node n of the network, the signal value is propagated along the nodes according to the following recursive rule:</p>
      <disp-formula id="equ-001">
        <mml:math id="eq-001">
          <mml:mrow>
            <mml:msub>
              <mml:mi>S</mml:mi>
              <mml:mi>n</mml:mi>
            </mml:msub>
            <mml:mo>=</mml:mo>
            <mml:msub>
              <mml:mi>U</mml:mi>
              <mml:mi>n</mml:mi>
            </mml:msub>
            <mml:mn>1</mml:mn>
            <mml:mo>−</mml:mo>
            <mml:mstyle displaystyle="true">
              <mml:munder>
                <mml:mo>∏</mml:mo>
                <mml:mrow>
                  <mml:mtable>
                    <mml:mtr>
                      <mml:mtd>
                        <mml:mrow>
                          <mml:msub>
                            <mml:mi>s</mml:mi>
                            <mml:mi>a</mml:mi>
                          </mml:msub>
                        </mml:mrow>
                      </mml:mtd>
                      <mml:mtd>
                        <mml:mi>A</mml:mi>
                      </mml:mtd>
                    </mml:mtr>
                  </mml:mtable>
                </mml:mrow>
              </mml:munder>
              <mml:mrow>
                <mml:mo stretchy="false">(</mml:mo>
                <mml:mn>1</mml:mn>
                <mml:mo>−</mml:mo>
                <mml:msub>
                  <mml:mi>s</mml:mi>
                  <mml:mi>a</mml:mi>
                </mml:msub>
                <mml:mo stretchy="false">)</mml:mo>
              </mml:mrow>
            </mml:mstyle>
            <mml:mstyle displaystyle="true">
              <mml:munder>
                <mml:mo>∏</mml:mo>
                <mml:mrow>
                  <mml:mtable>
                    <mml:mtr>
                      <mml:mtd>
                        <mml:mrow>
                          <mml:msub>
                            <mml:mi>s</mml:mi>
                            <mml:mi>i</mml:mi>
                          </mml:msub>
                        </mml:mrow>
                      </mml:mtd>
                      <mml:mtd>
                        <mml:mi>I</mml:mi>
                      </mml:mtd>
                    </mml:mtr>
                  </mml:mtable>
                </mml:mrow>
              </mml:munder>
              <mml:mrow>
                <mml:mo stretchy="false">(</mml:mo>
                <mml:mn>1</mml:mn>
                <mml:mo>−</mml:mo>
                <mml:msub>
                  <mml:mi>s</mml:mi>
                  <mml:mi>i</mml:mi>
                </mml:msub>
                <mml:mo stretchy="false">)</mml:mo>
              </mml:mrow>
            </mml:mstyle>
            <mml:mo stretchy="false">(</mml:mo>
            <mml:mn>1</mml:mn>
            <mml:mo stretchy="false">)</mml:mo>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p>Where <italic>S<sub>n</sub></italic> is the signal intensity for the current node <italic>n</italic>, <italic>v<sub>n</sub></italic> is its normalized value, <italic>A</italic> is the total number of activation signals (<italic>s<sub>a</sub></italic>), arriving to the current node from activation edges, <italic>I</italic> is the total number of inhibitory signals (<italic>s<sub>i</sub></italic>) arriving to the node from inhibition edges.</p>
      <p>The algorithm to compute the transmission of the signal along the network is a recursive method based on the Dijkstra algorithm [<xref rid="R45" ref-type="bibr">45</xref>]. Each time the signal value across a node is updated in a recursion and the difference with the previous value is greater than a threshold, all the nodes to which an edge arrives from the current updated node are marked to be updated. The recursion continues until the update in the values is below the threshold. The advantage if using an iterative method is that the signal becomes steady even in cases of loops in the pathway topology, allowing a more precise estimation of circuit activities. Many PAA methods simply cannot handle with loops and artificially disconnect them or even remove them from the calculations [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R13" ref-type="bibr">13</xref>–<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Figure <xref ref-type="fig" rid="F6">6</xref> represents the computation of the intensity of signal transmission across a node, and exemplifies in a simple scenario how the signal is transmitted across a circuit.</p>
    </sec>
    <sec id="s4_5">
      <title>Effector circuits and functional analysis</title>
      <p>Effector nodes at the end of the circuits trigger specific functions in the cell. These functions are defined here based on the annotations of the proteins contained in the effector node. Gene Ontology [<xref rid="R46" ref-type="bibr">46</xref>] (GO) terms corresponding to the biological process ontology (February 16, 2016 release) and molecular function keywords of Uniprot [<xref rid="R47" ref-type="bibr">47</xref>] (release of September 21, 2015) are used.</p>
      <p>The signal intensity received by the effector node can be propagated to the functions triggered by them following the same rationale of signal propagation along the circuits. Figure <xref ref-type="fig" rid="F5">5</xref> illustrates how effector circuits are composed by different canonical circuits and how functions can be triggered by several effector circuits.</p>
    </sec>
    <sec id="s4_6">
      <title>Straightforward integration of transcriptomic and genomic data</title>
      <p>Finally, the integration of genomic and transcriptomic data in the proposed modeling framework of signaling pathways is straightforward. In order to transmit the signal a protein needs to be present (gene expressed) and to be functional (harboring no impairing mutations). Genomic data can be integrated with transcriptomic data to infer combined gene activity and integrity (and consequently potential functionality). In the simplest approach [<xref rid="R9" ref-type="bibr">9</xref>] the normalized expression value of genes harboring mutations is multiplied by 0 if the pathogenicity (e.g. SIFT [<xref rid="R48" ref-type="bibr">48</xref>], PolyPhen [<xref rid="R49" ref-type="bibr">49</xref>]) and conservation indexes (e.g. phastCons [<xref rid="R50" ref-type="bibr">50</xref>]) are beyond a given threshold (taking into account the inheritance mode), or if the consequence type of the mutation (stop gain, stop loss, and splicing disrupting) is deleterious <italic>per se</italic>, because it is considered to produce a non-functional protein. The HiPathia program enables the analysis of mutations found in standard variant files (VCF) from whole exome/genome sequencing experiments in combination with gene expression values.</p>
    </sec>
    <sec id="s4_7">
      <title>Specificity of the method of canonical circuit activity analysis (CCAA)</title>
      <p>To estimate the false positive rate, different groups of N identical individuals were generated and further divided into two datasets that were compared to each other for finding differentially activated circuits. This comparison was repeated 2000 times for different data sizes (N = 20, 50, 100, 200 and 400 individuals) in three different scenarios: i) N individuals were randomly sampled among KIRC patients; ii) For each gene <italic>g</italic>, an empirical distribution of gene expression values was derived from the patients of the KIRC dataset. Specifically, the mean μ<sub>g</sub> and variance σ<sup>2</sup><sub>g</sub> was inferred for each gene <italic>g</italic> taking into account the gene expression values measured for these gene in all the samples. Then, N individuals were generated by simulating the gene expression values for each gene <italic>g</italic> as random numbers sampled from a normal distribution N(μ<sub>g</sub>,σ<sup>2</sup><sub>g</sub>); iii) N individuals were generated by simulating their gene expression values as random numbers from a normal distribution N(0.5, 0.05) as above.</p>
      <p>Since the individuals involved in the comparison were taken either from the same type of samples or were generated in the same way, any differential activation found can be considered a false positive. The comparisons were carried out for both, circuits and effector proteins.</p>
    </sec>
    <sec id="s4_8">
      <title>Sensitivity of the Canonical Circuit Activity Analysis (CCAA) method</title>
      <p>To estimate the true positive rate, we tested a scenario in which biological differences are expected. For this purpose, we used the two 2 cancers in Table <xref ref-type="table" rid="T2">2</xref> with more individuals, BRCA [<xref rid="R30" ref-type="bibr">30</xref>] and KIRC [<xref rid="R19" ref-type="bibr">19</xref>]. For each of the two cancers we generated 100 datasets of N=50,100,200 and 400 samples by sampling randomly both the normal and tumor samples in such a way that the normal/tumor proportion remained the same as in the original dataset (Table <xref ref-type="table" rid="T2">2</xref>). Specifically, for BRCA (with 113 normal tissue and 1057 tumor), N= 50, 100, 200 and 400 correspond to normal/tumor proportions of 5/45, 10/90, 19/181 and 39/361, respectively. In the case of KIRC (with 68 normal and 470 tumor) the respective proportions were 6/44, 13/87, 25/175 and 51/349. In total, we generated 2×100×4 = 800 datasets. CCAA was calculated at the level of signaling circuits and effector circuits for both datasets. The true positive rate was estimated as the number of cancer pathways containing one or more differentially activated circuits divided by the total number of cancer pathways. Although a gold standard is always difficult in this type of scenario, we can expect changes in the 14 cancer pathways, as defined in KEGG (Cancer pathways category, see Table <xref ref-type="table" rid="T3">3</xref>). Additionally, we produced an extended table of 49 cancer pathways curated by expert collaborators from the Valencia Institute of Oncology (IVO) (Table <xref ref-type="table" rid="T4">4</xref>).</p>
    </sec>
    <sec id="s4_9">
      <title>Comparison with other available methods for defining and scoring pathway activity</title>
      <p>We compared the reliability of the CCAA method proposed here to other proposals for defining sub-pathways and for calculating an activity score for them. Among the methods listed in Table <xref ref-type="table" rid="T1">1</xref> only nine could be applied to RNA-seq data and have software available for running them. These are: DEAP [<xref rid="R12" ref-type="bibr">12</xref>], subSPIA [<xref rid="R13" ref-type="bibr">13</xref>], using their own software, and topologyGSA [<xref rid="R14" ref-type="bibr">14</xref>], DEGraph [<xref rid="R6" ref-type="bibr">6</xref>], clipper [<xref rid="R5" ref-type="bibr">5</xref>], TAPPA [<xref rid="R15" ref-type="bibr">15</xref>], PRS [<xref rid="R16" ref-type="bibr">16</xref>], PWEA [<xref rid="R17" ref-type="bibr">17</xref>], implemented in the topaseq package [<xref rid="R18" ref-type="bibr">18</xref>]. The relative performance of the methods compared was derived from the estimation of their ratios of false positives and false negatives in a similar way than above. In order to estimate the false positives rate 12 cancer datasets (Table <xref ref-type="table" rid="T2">2</xref>) were used. For each cancer, 50 patients were randomly sampled 100 times. Any sampled set is divided into two equally sized subsets that are subsequently compared. Then, the 100 values obtained for each cancer are used to determine a mean value and a SD for the false positives ratio. The same 12 cancers (Table <xref ref-type="table" rid="T2">2</xref>) were used to estimate the true positive rates. For each cancer versus normal tissue comparison the number of significant cancer pathways was calculated and divided by the total number of cancer pathways. The ratios were calculated for both the 14 cancer pathways as defined in KEGG (Cancer pathways category, see Table <xref ref-type="table" rid="T3">3</xref>) and the extended list of 49 curated cancer pathways (Table <xref ref-type="table" rid="T4">4</xref>).</p>
    </sec>
    <sec id="s4_10">
      <title>Survival in cancer</title>
      <p>The KIRC TCGA samples contain survival information among the clinical data available. These can be used to check whether the circuit or function activities estimated for each patient have a relationship with survival or not. Kaplan-Meier (K-M) curves [<xref rid="R51" ref-type="bibr">51</xref>] were estimated using the function <italic>survdiff</italic> from the <italic>survival</italic> R package (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/survival/">https://cran.r-project.org/web/packages/survival/</ext-link>) for each signaling circuit, each effector circuit and each cell function (either Uniprot or GO definitions) with a significant difference of activity when cancers were compared to the corresponding controls. Specifically, the 10% of individuals presenting the highest (or lowest) activity were compared to the rest of them.</p>
    </sec>
    <sec id="s4_11">
      <title>Availability of data and materials</title>
      <p>A user-friendly web server that runs the code for carrying out the CCAA method is freely available at <ext-link ext-link-type="uri" xlink:href="http://hipathia.babelomics.org">http://hipathia.babelomics.org</ext-link>.</p>
      <p>The R code implementing the method is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/babelomics/hipathia">https://github.com/babelomics/hipathia</ext-link>.</p>
      <p>This work is supported by grants BIO2014-57291-R from the Spanish Ministry of Economy and Competitiveness and “Plataforma de Recursos Biomoleculares y Bioinformáticos” PT13/0001/0007 from the ISCIII, both co-funded with European Regional Development Funds (ERDF); PROMETEOII/2014/025 from the Generalitat Valenciana (GVA-FEDER); Fundació la Marató TV3 (ref. 20133134); and EU H2020-INFRADEV-1-2015-1 ELIXIR-EXCELERATE (ref. 676559) and EU FP7-People ITN Marie Curie Project (ref 316861).</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material" id="s5">
    <title>SUPPLEMENTARY MATERIALS FIGURES AND TABLES</title>
    <supplementary-material content-type="local-data" id="SD1">
      <media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-08-5160-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e2965" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD2">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s002.xlsx" orientation="portrait" xlink:type="simple" id="d35e2967" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD3">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s003.xlsx" orientation="portrait" xlink:type="simple" id="d35e2969" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD4">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s004.xlsx" orientation="portrait" xlink:type="simple" id="d35e2971" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD5">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s005.xlsx" orientation="portrait" xlink:type="simple" id="d35e2973" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD6">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s006.xlsx" orientation="portrait" xlink:type="simple" id="d35e2975" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD7">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s007.xlsx" orientation="portrait" xlink:type="simple" id="d35e2977" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD8">
      <media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-5160-s008.xlsx" orientation="portrait" xlink:type="simple" id="d35e2979" position="anchor"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We are very indebted to Drs. José Costa, from the Yale University School of Medicine, and Jose Antonio Lopez Guerrero, from the Valencian Institute of Oncology (IVO), for their valuable comments and help in the biological interpretation of the results found.</p>
  </ack>
  <fn-group>
    <fn fn-type="COI-statement">
      <p>
        <bold>CONFLICTS OF INTEREST</bold>
      </p>
      <p>The authors declare that they have no conflicts of interest</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="R1">
      <label>1</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brunner</surname>
            <given-names>HG</given-names>
          </name>
        </person-group>
        <article-title>The modular nature of genetic diseases</article-title>
        <source>Clin Genet</source>
        <year>2007</year>
        <volume>71</volume>
        <fpage>1</fpage>
        <lpage>11</lpage>
        <pub-id pub-id-type="pmid">17204041</pub-id>
      </element-citation>
    </ref>
    <ref id="R2">
      <label>2</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fey</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Halasz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dreidax</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kennedy</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Hastings</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Rauch</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Munoz</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Pilkington</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Fischer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Westermann</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kolch</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Kholodenko</surname>
            <given-names>BN</given-names>
          </name>
          <name>
            <surname>Croucher</surname>
            <given-names>DR</given-names>
          </name>
        </person-group>
        <article-title>Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients</article-title>
        <source>Sci Signal</source>
        <year>2015</year>
        <volume>8</volume>
        <fpage>ra130</fpage>
        <pub-id pub-id-type="pmid">26696630</pub-id>
      </element-citation>
    </ref>
    <ref id="R3">
      <label>3</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vidal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity</article-title>
        <source>Scientific reports</source>
        <year>2015</year>
        <volume>5</volume>
        <fpage>18494</fpage>
        <pub-id pub-id-type="pmid">26678097</pub-id>
      </element-citation>
    </ref>
    <ref id="R4">
      <label>4</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaakkola</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Elo</surname>
            <given-names>LL</given-names>
          </name>
        </person-group>
        <article-title>Empirical comparison of structure-based pathway methods</article-title>
        <source>Briefings in bioinformatics</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>336</fpage>
        <lpage>345</lpage>
        <pub-id pub-id-type="pmid">26197809</pub-id>
      </element-citation>
    </ref>
    <ref id="R5">
      <label>5</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martini</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sales</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Massa</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Chiogna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Romualdi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Along signal paths: an empirical gene set approach exploiting pathway topology</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>e19</fpage>
        <pub-id pub-id-type="pmid">23002139</pub-id>
      </element-citation>
    </ref>
    <ref id="R6">
      <label>6</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jacob</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Neuvial</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Dudoit</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>More power via graph-structured tests for differential expression of gene networks</article-title>
        <source>Ann Appl Stat</source>
        <year>2012</year>
        <volume>6</volume>
        <fpage>561</fpage>
        <lpage>600</lpage>
      </element-citation>
    </ref>
    <ref id="R7">
      <label>7</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Carbonell</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Sanchez</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Medina</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Inferring the functional effect of gene expression changes in signaling pathways</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>W213</fpage>
        <lpage>217</lpage>
        <pub-id pub-id-type="pmid">23748960</pub-id>
      </element-citation>
    </ref>
    <ref id="R8">
      <label>8</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vidal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Minguez</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Conesa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tarazona</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Armero</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vidal-Puig</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Montaner</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Understanding disease mechanisms with models of signaling pathway activities</article-title>
        <source>BMC Syst Biol</source>
        <year>2014</year>
        <volume>8</volume>
        <fpage>121</fpage>
        <pub-id pub-id-type="pmid">25344409</pub-id>
      </element-citation>
    </ref>
    <ref id="R9">
      <label>9</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hernansaiz-Ballesteros</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Aleman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Medina</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Assessing the impact of mutations found in next generation sequencing data over human signaling pathways</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>W270</fpage>
        <lpage>275</lpage>
        <pub-id pub-id-type="pmid">25883139</pub-id>
      </element-citation>
    </ref>
    <ref id="R10">
      <label>10</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>WE</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rabinovic</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Adjusting batch effects in microarray expression data using empirical Bayes methods</article-title>
        <source>Biostatistics</source>
        <year>2007</year>
        <volume>8</volume>
        <fpage>118</fpage>
        <lpage>127</lpage>
        <pub-id pub-id-type="pmid">16632515</pub-id>
      </element-citation>
    </ref>
    <ref id="R11">
      <label>11</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Oshlack</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title>
        <source>Genome Biol</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>R25</fpage>
        <pub-id pub-id-type="pmid">20196867</pub-id>
      </element-citation>
    </ref>
    <ref id="R12">
      <label>12</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Haynes</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Higdon</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Stanberry</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kolker</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Differential expression analysis for pathways</article-title>
        <source>PLoS Comput Biol</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>e1002967</fpage>
        <pub-id pub-id-type="pmid">23516350</pub-id>
      </element-citation>
    </ref>
    <ref id="R13">
      <label>13</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Shang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Subpathway Analysis based on Signaling-Pathway Impact Analysis of Signaling Pathway</article-title>
        <source>PLoS ONE</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>e0132813</fpage>
        <pub-id pub-id-type="pmid">26207919</pub-id>
      </element-citation>
    </ref>
    <ref id="R14">
      <label>14</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Massa</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Chiogna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Romualdi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Gene set analysis exploiting the topology of a pathway</article-title>
        <source>BMC Syst Biol</source>
        <year>2010</year>
        <volume>4</volume>
        <fpage>121</fpage>
        <pub-id pub-id-type="pmid">20809931</pub-id>
      </element-citation>
    </ref>
    <ref id="R15">
      <label>15</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>TAPPA: topological analysis of pathway phenotype association</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <fpage>3100</fpage>
        <lpage>3102</lpage>
        <pub-id pub-id-type="pmid">17890270</pub-id>
      </element-citation>
    </ref>
    <ref id="R16">
      <label>16</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ibrahim</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Jassim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cawthorne</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Langlands</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>A topology-based score for pathway enrichment</article-title>
        <source>J Comput Biol</source>
        <year>2012</year>
        <volume>19</volume>
        <fpage>563</fpage>
        <lpage>573</lpage>
        <pub-id pub-id-type="pmid">22468678</pub-id>
      </element-citation>
    </ref>
    <ref id="R17">
      <label>17</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hung</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Whitfield</surname>
            <given-names>TW</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Weng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>DeLisi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Identification of functional modules that correlate with phenotypic difference: the influence of network topology</article-title>
        <source>Genome Biol</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>R23</fpage>
        <pub-id pub-id-type="pmid">20187943</pub-id>
      </element-citation>
    </ref>
    <ref id="R18">
      <label>18</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ihnatova</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Budinska</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>ToPASeq: an R package for topology-based pathway analysis of microarray and RNA-Seq data</article-title>
        <source>BMC Bioinformatics</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>350</fpage>
        <pub-id pub-id-type="pmid">26514335</pub-id>
      </element-citation>
    </ref>
    <ref id="R19">
      <label>19</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research Network</collab>
        </person-group>
        <article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>499</volume>
        <fpage>43</fpage>
        <lpage>49</lpage>
        <pub-id pub-id-type="pmid">23792563</pub-id>
      </element-citation>
    </ref>
    <ref id="R20">
      <label>20</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hanahan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Hallmarks of cancer: the next generation</article-title>
        <source>Cell</source>
        <year>2011</year>
        <volume>144</volume>
        <fpage>646</fpage>
        <lpage>674</lpage>
        <pub-id pub-id-type="pmid">21376230</pub-id>
      </element-citation>
    </ref>
    <ref id="R21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>ZQ</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>QY</given-names>
          </name>
        </person-group>
        <article-title>Temporal Identification of Dysregulated Genes and Pathways in Clear Cell Renal Cell Carcinoma Based on Systematic Tracking of Disrupted Modules</article-title>
        <source>Computational and mathematical methods in medicine</source>
        <year>2015</year>
        <volume>2015</volume>
        <fpage>313740</fpage>
        <pub-id pub-id-type="pmid">26543493</pub-id>
      </element-citation>
    </ref>
    <ref id="R22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bonelli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tuccillo</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Borrelli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schiattarella</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Buonaguro</surname>
            <given-names>FM</given-names>
          </name>
        </person-group>
        <article-title>CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity</article-title>
        <source>BioMed research international</source>
        <year>2014</year>
        <year>2014</year>
      </element-citation>
    </ref>
    <ref id="R23">
      <label>23</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hsu</surname>
            <given-names>PP</given-names>
          </name>
          <name>
            <surname>Sabatini</surname>
            <given-names>DM</given-names>
          </name>
        </person-group>
        <article-title>Cancer cell metabolism: Warburg and beyond</article-title>
        <source>Cell</source>
        <year>2008</year>
        <volume>134</volume>
        <fpage>703</fpage>
        <lpage>707</lpage>
        <pub-id pub-id-type="pmid">18775299</pub-id>
      </element-citation>
    </ref>
    <ref id="R24">
      <label>24</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Chakrabarti</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Gluconeogenesis combats cancer: opening new doors in cancer biology</article-title>
        <source>Cell death &amp; disease</source>
        <year>2015</year>
        <volume>6</volume>
        <fpage>e1872</fpage>
        <pub-id pub-id-type="pmid">26335714</pub-id>
      </element-citation>
    </ref>
    <ref id="R25">
      <label>25</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yarden</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sliwkowski</surname>
            <given-names>MX</given-names>
          </name>
        </person-group>
        <article-title>Untangling the ErbB signalling network</article-title>
        <source>Nature reviews Molecular cell biology</source>
        <year>2001</year>
        <volume>2</volume>
        <fpage>127</fpage>
        <lpage>137</lpage>
        <pub-id pub-id-type="pmid">11252954</pub-id>
      </element-citation>
    </ref>
    <ref id="R26">
      <label>26</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wood</surname>
            <given-names>LD</given-names>
          </name>
          <name>
            <surname>Parsons</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sjöblom</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Leary</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Boca</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Barber</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ptak</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>The genomic landscapes of human breast and colorectal cancers</article-title>
        <source>Science</source>
        <year>2007</year>
        <volume>318</volume>
        <fpage>1108</fpage>
        <lpage>1113</lpage>
        <pub-id pub-id-type="pmid">17932254</pub-id>
      </element-citation>
    </ref>
    <ref id="R27">
      <label>27</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Genomics and transcriptomics in drug discovery</article-title>
        <source>Drug Discov Today</source>
        <year>2014</year>
        <volume>19</volume>
        <fpage>126</fpage>
        <lpage>132</lpage>
        <pub-id pub-id-type="pmid">23773860</pub-id>
      </element-citation>
    </ref>
    <ref id="R28">
      <label>28</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fryburg</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Laifenfeld</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>de Graaf</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease</article-title>
        <source>Drug Discov Today</source>
        <year>2014</year>
        <volume>19</volume>
        <fpage>108</fpage>
        <lpage>112</lpage>
        <pub-id pub-id-type="pmid">23872468</pub-id>
      </element-citation>
    </ref>
    <ref id="R29">
      <label>29</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research Network</collab>
        </person-group>
        <article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>507</volume>
        <fpage>315</fpage>
        <lpage>322</lpage>
        <pub-id pub-id-type="pmid">24476821</pub-id>
      </element-citation>
    </ref>
    <ref id="R30">
      <label>30</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Network</collab>
        </person-group>
        <article-title>Comprehensive molecular portraits of human breast tumours</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>490</volume>
        <fpage>61</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="pmid">23000897</pub-id>
      </element-citation>
    </ref>
    <ref id="R31">
      <label>31</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research Network</collab>
        </person-group>
        <article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>487</volume>
        <fpage>330</fpage>
        <lpage>337</lpage>
        <pub-id pub-id-type="pmid">22810696</pub-id>
      </element-citation>
    </ref>
    <ref id="R32">
      <label>32</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Network</collab>
        </person-group>
        <article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title>
        <source>Nature</source>
        <year>2015</year>
        <volume>517</volume>
        <fpage>576</fpage>
        <lpage>582</lpage>
        <pub-id pub-id-type="pmid">25631445</pub-id>
      </element-citation>
    </ref>
    <ref id="R33">
      <label>33</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Linehan</surname>
            <given-names>WM</given-names>
          </name>
          <name>
            <surname>Spellman</surname>
            <given-names>PT</given-names>
          </name>
          <name>
            <surname>Ricketts</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Creighton</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Fei</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vocke</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Peto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Al Mamun</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Shinbrot</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sethi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Brooks</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rathmell</surname>
            <given-names>WK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma</article-title>
        <source>N Engl J Med</source>
        <year>2016</year>
        <volume>374</volume>
        <fpage>135</fpage>
        <lpage>145</lpage>
        <pub-id pub-id-type="pmid">26536169</pub-id>
      </element-citation>
    </ref>
    <ref id="R34">
      <label>34</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research Network</collab>
        </person-group>
        <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>511</volume>
        <fpage>543</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="pmid">25079552</pub-id>
      </element-citation>
    </ref>
    <ref id="R35">
      <label>35</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research Network</collab>
        </person-group>
        <article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>489</volume>
        <fpage>519</fpage>
        <lpage>525</lpage>
        <pub-id pub-id-type="pmid">22960745</pub-id>
      </element-citation>
    </ref>
    <ref id="R36">
      <label>36</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Network</collab>
        </person-group>
        <source>The Molecular Taxonomy of Primary Prostate Cancer. Cell</source>
        <year>2015</year>
        <volume>163</volume>
        <fpage>1011</fpage>
        <lpage>1025</lpage>
      </element-citation>
    </ref>
    <ref id="R37">
      <label>37</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Cancer Genome Atlas Research</collab>
        </person-group>
        <article-title>Network. Integrated genomic characterization of papillary thyroid carcinoma</article-title>
        <source>Cell</source>
        <year>2014</year>
        <volume>159</volume>
        <fpage>676</fpage>
        <lpage>690</lpage>
        <pub-id pub-id-type="pmid">25417114</pub-id>
      </element-citation>
    </ref>
    <ref id="R38">
      <label>38</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kandoth</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schultz</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Akbani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Robertson</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Pashtan</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Yau</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Laird</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Kucherlapati</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated genomic characterization of endometrial carcinoma</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>497</volume>
        <fpage>67</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="pmid">23636398</pub-id>
      </element-citation>
    </ref>
    <ref id="R39">
      <label>39</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawashima</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Data, information, knowledge and principle: back to metabolism in KEGG</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>D199</fpage>
        <lpage>205</lpage>
        <pub-id pub-id-type="pmid">24214961</pub-id>
      </element-citation>
    </ref>
    <ref id="R40">
      <label>40</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Croft</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mundo</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Haw</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Milacic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Weiser</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Caudy</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Garapati</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kamdar</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Jassal</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jupe</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Matthews</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>May</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Palatnik</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rothfels</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Reactome pathway knowledgebase</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>D472</fpage>
        <lpage>477</lpage>
        <pub-id pub-id-type="pmid">24243840</pub-id>
      </element-citation>
    </ref>
    <ref id="R41">
      <label>41</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rix</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Bai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Edwards</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Colinge</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bennett</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Eschrich</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Superti-Furga</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Koomen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haura</surname>
            <given-names>EB</given-names>
          </name>
        </person-group>
        <article-title>A chemical and phosphoproteomic characterization of dasatinib action in lung cancer</article-title>
        <source>Nat Chem Biol</source>
        <year>2010</year>
        <volume>6</volume>
        <fpage>291</fpage>
        <lpage>299</lpage>
        <pub-id pub-id-type="pmid">20190765</pub-id>
      </element-citation>
    </ref>
    <ref id="R42">
      <label>42</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mitsos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Melas</surname>
            <given-names>IN</given-names>
          </name>
          <name>
            <surname>Siminelakis</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chairakaki</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Saez-Rodriguez</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Alexopoulos</surname>
            <given-names>LG</given-names>
          </name>
        </person-group>
        <article-title>Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data</article-title>
        <source>PLoS Comput Biol</source>
        <year>2009</year>
        <volume>5</volume>
        <fpage>e1000591</fpage>
        <pub-id pub-id-type="pmid">19997482</pub-id>
      </element-citation>
    </ref>
    <ref id="R43">
      <label>43</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Efroni</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schaefer</surname>
            <given-names>CF</given-names>
          </name>
          <name>
            <surname>Buetow</surname>
            <given-names>KH</given-names>
          </name>
        </person-group>
        <article-title>Identification of key processes underlying cancer phenotypes using biologic pathway analysis</article-title>
        <source>PLoS ONE</source>
        <year>2007</year>
        <volume>2</volume>
        <fpage>e425</fpage>
        <pub-id pub-id-type="pmid">17487280</pub-id>
      </element-citation>
    </ref>
    <ref id="R44">
      <label>44</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pihur</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Datta</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Datta</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Reconstruction of genetic association networks from microarray data: a partial least squares approach</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>561</fpage>
        <lpage>568</lpage>
        <pub-id pub-id-type="pmid">18204062</pub-id>
      </element-citation>
    </ref>
    <ref id="R45">
      <label>45</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dijkstra</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>A note on two problems in connexion with graphs</article-title>
        <source>Numerische Mathematik</source>
        <year>1959</year>
        <volume>1</volume>
        <fpage>269</fpage>
        <lpage>271</lpage>
      </element-citation>
    </ref>
    <ref id="R46">
      <label>46</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashburner</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ball</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Blake</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Botstein</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Cherry</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Dolinski</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Dwight</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Eppig</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Hill</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Issel-Tarver</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kasarskis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Matese</surname>
            <given-names>JC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene ontology: tool for the unification of biology</article-title>
        <source>The Gene Ontology Consortium. Nat Genet</source>
        <year>2000</year>
        <volume>25</volume>
        <fpage>25</fpage>
        <lpage>29</lpage>
        <pub-id pub-id-type="pmid">10802651</pub-id>
      </element-citation>
    </ref>
    <ref id="R47">
      <label>47</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>UniProt_Consortium</collab>
        </person-group>
        <article-title>UniProt: a hub for protein information</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>D204</fpage>
        <lpage>212</lpage>
        <pub-id pub-id-type="pmid">25348405</pub-id>
      </element-citation>
    </ref>
    <ref id="R48">
      <label>48</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Henikoff</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ng</surname>
            <given-names>PC</given-names>
          </name>
        </person-group>
        <article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>
        <source>Nat Protoc</source>
        <year>2009</year>
        <volume>4</volume>
        <fpage>1073</fpage>
        <lpage>1081</lpage>
        <pub-id pub-id-type="pmid">19561590</pub-id>
      </element-citation>
    </ref>
    <ref id="R49">
      <label>49</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramensky</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Bork</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sunyaev</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Human non-synonymous SNPs: server and survey</article-title>
        <source>Nucleic Acids Res</source>
        <year>2002</year>
        <volume>30</volume>
        <fpage>3894</fpage>
        <lpage>3900</lpage>
        <pub-id pub-id-type="pmid">12202775</pub-id>
      </element-citation>
    </ref>
    <ref id="R50">
      <label>50</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Siepel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bejerano</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pedersen</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Hinrichs</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rosenbloom</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Clawson</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Spieth</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hillier</surname>
            <given-names>LW</given-names>
          </name>
          <name>
            <surname>Richards</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Weinstock</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Gibbs</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Kent</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Haussler</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes</article-title>
        <source>Genome Res</source>
        <year>2005</year>
        <volume>15</volume>
        <fpage>1034</fpage>
        <lpage>1050</lpage>
        <pub-id pub-id-type="pmid">16024819</pub-id>
      </element-citation>
    </ref>
    <ref id="R51">
      <label>51</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kaplan</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Meier</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Nonparametric estimation from incomplete observations</article-title>
        <source>Journal of the American Statistical Association</source>
        <year>1958</year>
        <volume>53</volume>
        <fpage>457</fpage>
        <lpage>481</lpage>
      </element-citation>
    </ref>
    <ref id="R52">
      <label>52</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Koumakis</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Potamias</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tsiknakis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zervakis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Moustakis</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>Integrating Microarray Data and GRNs</article-title>
        <source>Methods Mol Biol</source>
        <year>2015</year>
      </element-citation>
    </ref>
    <ref id="R53">
      <label>53</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>A network flow-based method to predict anticancer drug sensitivity</article-title>
        <source>PLoS ONE</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>e0127380</fpage>
        <pub-id pub-id-type="pmid">25992881</pub-id>
      </element-citation>
    </ref>
    <ref id="R54">
      <label>54</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nam</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Kook</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kwon</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Powis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YH</given-names>
          </name>
        </person-group>
        <article-title>PATHOME: an algorithm for accurately detecting differentially expressed subpathways</article-title>
        <source>Oncogene</source>
        <year>2014</year>
        <volume>33</volume>
        <fpage>4941</fpage>
        <lpage>4951</lpage>
        <pub-id pub-id-type="pmid">24681952</pub-id>
      </element-citation>
    </ref>
    <ref id="R55">
      <label>55</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pepe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Grassi</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Investigating perturbed pathway modules from gene expression data via structural equation models</article-title>
        <source>BMC Bioinformatics</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>132</fpage>
        <pub-id pub-id-type="pmid">24885496</pub-id>
      </element-citation>
    </ref>
    <ref id="R56">
      <label>56</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sales</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Calura</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Martini</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Romualdi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Graphite Web: Web tool for gene set analysis exploiting pathway topology</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>W89</fpage>
        <lpage>97</lpage>
        <pub-id pub-id-type="pmid">23666626</pub-id>
      </element-citation>
    </ref>
    <ref id="R57">
      <label>57</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Judeh</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>TEAK: topology enrichment analysis framework for detecting activated biological subpathways</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>1425</fpage>
        <lpage>1437</lpage>
        <pub-id pub-id-type="pmid">23268448</pub-id>
      </element-citation>
    </ref>
    <ref id="R58">
      <label>58</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rivera</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Tyler</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Murali</surname>
            <given-names>TM</given-names>
          </name>
        </person-group>
        <article-title>Sensitive detection of pathway perturbations in cancers</article-title>
        <source>BMC Bioinformatics</source>
        <year>2012</year>
        <volume>13</volume>
        <fpage>S9</fpage>
      </element-citation>
    </ref>
    <ref id="R59">
      <label>59</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>A sub-pathway-based approach for identifying drug response principal network</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>649</fpage>
        <lpage>654</lpage>
        <pub-id pub-id-type="pmid">21186246</pub-id>
      </element-citation>
    </ref>
    <ref id="R60">
      <label>60</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ulitsky</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Krishnamurthy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Karp</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Shamir</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>DEGAS: de novo discovery of dysregulated pathways in human diseases</article-title>
        <source>PLoS ONE</source>
        <year>2010</year>
        <volume>5</volume>
        <fpage>e13367</fpage>
        <pub-id pub-id-type="pmid">20976054</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
